The Effect of Intracapsular Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Laparoscopic Myomectomy Operations

Launched by WAEL ELBANNA CLINIC · Dec 22, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two medications, Terlipressin and Carbetocin, to see how well they help maintain hemoglobin levels and reduce blood loss during laparoscopic myomectomy surgeries. A laparoscopic myomectomy is a minimally invasive procedure to remove fibroids (myomas) from the uterus, which can cause symptoms like pelvic pain, heavy periods, or infertility. The trial is looking for women between the ages of 16 and 45 who are in good health, have specific types of myomas, and meet other criteria.

Participants in the study will receive one of the two injections during their surgery and will be monitored for their blood levels and any side effects. It’s important for potential participants to know that they should not have certain medical conditions, like previous surgeries for myomas or bleeding disorders, to be eligible. If you meet the criteria and are interested, this study could help improve care for women undergoing this type of surgery.

Gender

FEMALE

Eligibility criteria

• • Inclusion Criteria
• • 1. Women aged 16-45 years
• • 2. Appropriate medical status for laparoscopic surgery (largest myoma ≤15 cm)
• • 3. Baseline hemoglobin ≥9 g/dl
• • 4. No contra-indications to the use of glyopressin or carbitocin
• • 5. Myoma-related symptoms, such as pelvic pressure or pain, menorrhagia, or infertility
• • 6. Not pregnant at the time of presentation (i.e., negative urine pregnancy test or last menstrual period within the last 4 weeks)
• Exclusion Criteria:
• • 1. Previous myomectomy
• • 2. History of bleeding disorders
• • 3. Concurrent anticoagulation therapy
• • 4. History of Uncontrolled ischaemic heart disease
• • 5. Any pelvic abnormalities requiring concomitant surgery
• • 6. Treatment with a GnRH agonist or ulipristal acetate within three months preceding surgery
• • 7. Inability to understand and provide written informed consent